Warning: Undefined array key "file" in /home/www/wwwroot/HTML/www.exportstart.com/wp-content/themes/1198/header.php on line 7

Warning: Undefined array key "title" in /home/www/wwwroot/HTML/www.exportstart.com/wp-content/themes/1198/header.php on line 7

Warning: Undefined array key "title" in /home/www/wwwroot/HTML/www.exportstart.com/wp-content/themes/1198/header.php on line 7

Milrinone

Pharmaceutical Chemicals Milrinone Raw Powder CAS 78415-72-2

 

  • Enw Cynnyrch:

    Milrinone

  • Gradd:

    Gradd fferyllol

  • Priodweddau:

    Powdr gwyn

  • Pacio:

    25kg / drwm

  • MOQ:

    1 kilo

  • Storio:Lle Sych Cŵl
  • Oes silff:2 flynedd


Manylion

Tagiau

Disgrifiad o'r Cynnyrch

 

Milrinone is a phosphodiesterase inhibitor, a cardiotonic drug with positive inotropic and vasodilating effects, which can be used to treat acute or chronic refractory congestive heart failure.

Millinone is a cardiotropic drug, belonging to phosphodiesterase inhibitors. By inhibiting phosphodiesterase, the drug can increase the concentration of cyclic adenosine phosphate and calcium in cardiomyocytes, thereby effectively strengthening myocardial contractility and increasing cardiac output, so as to exert positive muscle strength. In addition, Milrinone can also play a vasodilator role by directly acting on the small arteries.

 

Disgrifiad o'r Cynnyrch
Nodweddion

 

milrinone supports ventricular functioning of the heart by decreasing the degradation of cAMP and thus increasing phosphorylation levels of many components in the heart that contribute to contractility and heart rate. Milrinone use following cardiac surgery has been under some debate because of the potential increase risk of postoperative atrial arrhythmias. However, in the short term milrinone has been deemed beneficial to those experiencing heart failure and an effective therapy to maintain heart function following cardiac surgeries. There is no evidence of any long term beneficial effects on survival. 

Cais

 


Milrinone, is a medication used in patients who have heart failure. It is a phosphodiesterase 3 inhibitor that works to increase the heart's contractility and decrease pulmonary vascular resistance. Milrinone also works to vasodilate which helps alleviate increased pressures (afterload) on the heart, thus improving its pumping action. While it has been used in people with heart failure for many years, recent studies suggest that milrinone may exhibit some negative side effects that have caused some debate about its use clinically.
Overall, milrinone supports ventricular functioning of the heart by decreasing the degradation of cAMP and thus increasing phosphorylation levels of many components in the heart that contribute to contractility and heart rate. Milrinone use following cardiac surgery has been under some debate because of the potential increase risk of postoperative atrial arrhythmias. However, in the short term milrinone has been deemed beneficial to those experiencing heart failure and an effective therapy to maintain heart function following cardiac surgeries. There is no evidence of any long term beneficial effects on survival. 

 

Manteision

 

Mae gennym lawer o ffatrïoedd o ansawdd uchel gyda chydweithrediad dwfn, a all ddarparu cynhyrchion o ansawdd uchel a phrisiau cystadleuol i chi. A gallwn hefyd roi gostyngiadau ar gyfer swmp-brynu. Mae amser dosbarthu tua 3-20 diwrnod ar ôl cadarnhad taliad.

 

 

Manyleb

 

Dadansoddi
Manyleb
Canlyniad
Test method
Physical Description
 
 
 
Ymddangosiad
White Powder
White Powder
Visual
Arogl
Characteristic
Characteristic
Organoleptic
Particle size
90% pass 80 mesh
90% pass 80 mesh
80 Mesh Screen
Chemical Tests
 
 
 
Assay (Lutein)
99%
90.15%
HPLC
Loss on drying
5.0% Max
1.82%
5g/105ºC/2hrs
Ash Contents
5.0% Max
1.12%
2g/525ºC/3hrs
Residual Solvents
50.0 ppm, Only Ethanol
<30.0 ppm
/
Heavy metals
5.0 ppm Max
<3.0 ppm
AAS
Lead
3.0 ppm Max
<1.0 ppm
AAS
Arsenic
3.0 ppm Max
<1.0 ppm
AAS
Microbiology Control
 
 
 
Total Bacteria Count
1,000cfu/g Max
<280cfu/g
AOAC
Yeast & Mold
100cfu/g Max
<10cfu/g
AOAC
Coliform
30.0 MPN/g Max
<3.0 MPN/g
AOAC
Casgliad
Complies with the standards.
General Status
Non-GMO, ISO Certificated.

 

Gwybodaeth cynnyrch:

 

Milrinone is a PDE3 (phosphodiesterase 3) inhibitor that exhibits vasodilator and positive inotropic effects. Milrinone's positive inotropic activity can be inhibited by carbachol (sc-202092). Research indicates that Milrinone can increase platelets and enhance cAMP levels. Milrinone is an inhibitor of PDE3A and PDE3B.
Milrinone, commonly known and marketed as the drug Primacor, is a medication used in patients suffering from heart failure. Milrinone is a phosphodiesterase 3 inhibitor that works to increase the heart's contractility. Milrinone also works to vasodilate vessels which helps alleviate increased pressures (afterload) on the heart, thus improving its pumping action. Milrinone has been used in those suffering from heart failure for many years.

Cludo a thalu

 

 

 

FAQ

 

1. Ydych chi'n ffatri neu'n gwmni masnachu?
Rydym yn gwmni sy'n integreiddio diwydiant a masnach, yn darparu gwasanaeth un-stop. Gellid derbyn OEM.

2. A ydych chi'n darparu samplau? A yw'n rhad ac am ddim neu'n ychwanegol?
Samplau am ddim. Mae angen talu ffi cludo nwyddau'r sampl gan eich ochr chi.

3. A oes gennych unrhyw dystysgrifau sy'n ymwneud â rheoli ansawdd?
Ardystiad ISO 9001: 2008 i sicrhau ansawdd.

4. Beth ddylwn i ei ddarparu i gael dyfynbris?
Mae Pls yn rhoi gwybod i ni am y math o gynnyrch sydd ei angen arnoch, archebwch faint, cyfeiriad a gofynion penodol. Bydd y dyfynbris yn cael ei wneud ar gyfer eich cyfeirnod mewn pryd.

5. Pa fath o ddull talu sydd orau gennych chi? Pa fath o delerau sy'n cael eu derbyn?
Telerau Cyflwyno a Dderbynnir: FOB, CFR, CIF, EXW;
Arian Talu a Dderbynnir: USD;
Math o Daliad a Dderbynnir: T / T, Western Union; Paypal, Sicrwydd Masnach.
Iaith a siaredir: Saesneg.

 

Os oes gennych ddiddordeb yn ein cynnyrch, gallwch ddewis gadael eich gwybodaeth yma, a byddwn yn cysylltu â chi yn fuan.


Ysgrifennwch eich neges yma a'i hanfon atom